WBC count and immunophenotypic characteristics of APL cases
| Groups (cases) . | WBC count, ×109 cells per L . | HLA-DR (%) . | CD34 (%) . | CD13 (%) . | CD33 (%) . | CD56 (%) . |
|---|---|---|---|---|---|---|
| PML/RARA+(50/69)* | ||||||
| t(15;17) control group (20/20) | (20/20)† | − (19/20)‡ | − (19/20) | + (19/20) | + (16/20) | − (20/20) |
| Range | 0.5-86.1 | 0-371-153 | 0-46 | 8-98 | 0-98 | 0-8 |
| Median | 1.7 | 0 | 0 | 79 | 74 | 0 |
| Insertions (16/28) | (27/28) | − (13/14) | − (12/15) | + (15/16) | + (14/14) | − (4/5) |
| Range | 0.2-257 | 0-25 | 0-74 | 0-98 | 30 -100 | 0-30 |
| Median | 4.4 | 7 | 4 | 85 | 91 | 1 |
| Complex (10/14) | (13/14) | − (9/10) | + (6/10)1-155 | + (9/9) | + (8/9) | − (2/2) |
| Range | 0.7-60 | 0-84 | 0-91 | 30-94 | 20-97 | 0-2 |
| Median | 3.1 | 6 | 55 | 60 | 53 | 1 |
| ider(17) (4/7) | (7/7) | − (3/4) | − (4/4) | + (4/4) | − (3/4) | − (1/1) |
| Range | 0.8-10.8 | 0-43 | 0-3 | 46-97 | 0-85 | 0 |
| Median | 2.8 | 0 | 1 | 69 | 5 | 0 |
| PLZF/RARA+(7/11) | (11/11) | − (7/7) | − (7/7) | + (7/7) | + (6/7) | + (4/6)1-154 |
| Range | 2-69.5 | 0-13 | 0-3 | 77-100 | 0-100 | 0-100 |
| Median | 9.9 | 1 | 0 | 96 | 93 | 70 |
| t(5;17) (2/2) | ||||||
| NPM/RARA(1/1) | 17 | − 0 | − 0 | − 6 | + 97 | − 6 |
| der (5) t(5;17) | 43.1 | − 9 | − 0 | − 13 | + 83 | − 0 |
| RARA not rearranged (4/5) | (5/5) | − (4/4) | − (3/4) | + (3/4) | + (3/4) | − (2/2) |
| Range | 3.3-84 | 0-7 | 0-22 | 1-98 | 1-99 | 1-9 |
| Median | 11.3 | 2 | 1 | 82 | 89 | 5 |
| Groups (cases) . | WBC count, ×109 cells per L . | HLA-DR (%) . | CD34 (%) . | CD13 (%) . | CD33 (%) . | CD56 (%) . |
|---|---|---|---|---|---|---|
| PML/RARA+(50/69)* | ||||||
| t(15;17) control group (20/20) | (20/20)† | − (19/20)‡ | − (19/20) | + (19/20) | + (16/20) | − (20/20) |
| Range | 0.5-86.1 | 0-371-153 | 0-46 | 8-98 | 0-98 | 0-8 |
| Median | 1.7 | 0 | 0 | 79 | 74 | 0 |
| Insertions (16/28) | (27/28) | − (13/14) | − (12/15) | + (15/16) | + (14/14) | − (4/5) |
| Range | 0.2-257 | 0-25 | 0-74 | 0-98 | 30 -100 | 0-30 |
| Median | 4.4 | 7 | 4 | 85 | 91 | 1 |
| Complex (10/14) | (13/14) | − (9/10) | + (6/10)1-155 | + (9/9) | + (8/9) | − (2/2) |
| Range | 0.7-60 | 0-84 | 0-91 | 30-94 | 20-97 | 0-2 |
| Median | 3.1 | 6 | 55 | 60 | 53 | 1 |
| ider(17) (4/7) | (7/7) | − (3/4) | − (4/4) | + (4/4) | − (3/4) | − (1/1) |
| Range | 0.8-10.8 | 0-43 | 0-3 | 46-97 | 0-85 | 0 |
| Median | 2.8 | 0 | 1 | 69 | 5 | 0 |
| PLZF/RARA+(7/11) | (11/11) | − (7/7) | − (7/7) | + (7/7) | + (6/7) | + (4/6)1-154 |
| Range | 2-69.5 | 0-13 | 0-3 | 77-100 | 0-100 | 0-100 |
| Median | 9.9 | 1 | 0 | 96 | 93 | 70 |
| t(5;17) (2/2) | ||||||
| NPM/RARA(1/1) | 17 | − 0 | − 0 | − 6 | + 97 | − 6 |
| der (5) t(5;17) | 43.1 | − 9 | − 0 | − 13 | + 83 | − 0 |
| RARA not rearranged (4/5) | (5/5) | − (4/4) | − (3/4) | + (3/4) | + (3/4) | − (2/2) |
| Range | 3.3-84 | 0-7 | 0-22 | 1-98 | 1-99 | 1-9 |
| Median | 11.3 | 2 | 1 | 82 | 89 | 5 |
The positivity of each immunophenotype is given on the left, the indicated characteristics (number of cases and percentages) on the right.
Indicates the number of cases with available phenotype/total number of cases.
Indicates the number of cases with available WBC/total number of cases.
Indicates the number of positive (+) or negative (−) cases/number of tested cases, the cut-off is more than 20% positive cells.
Indicates the percentage of positive cells.
P = .002, comparing CD34 positivity between complex cases and noncomplex cases in the PML/RARAgroup; CD34 positivity among complex cases reflected an association with M3v morphology.
P = .001, comparing CD56 positivity between PLZF/RARA and PML/RARA cases; P = .0008, comparing CD56 positivity between PLZF/RARA and all non-PLZF/RARA cases.